Rodin, Danielle
Sutradhar, Rinku
Jerzak, Katarzyna J.
Hahn, Ezra
Nguyen, Lena
Castelo, Matthew
Fatiregun, Omolara
Fong, Cindy
Mata, Danilo Giffoni M. M.
Trebinjac, Sabina
Paszat, Lawrence
Rakovitch, Eileen http://orcid.org/0000-0001-9647-2851
Funding for this research was provided by:
E Rakovitch holds the LC Campbell Breast Cancer Research Chair
Article History
Received: 13 March 2023
Accepted: 24 May 2023
First Online: 16 June 2023
Declarations
:
: E Rakovitch has received research grant funding from Genomic Health Inc. outside of the submitted work. K.J.J reports personal fees from Amgen, AstraZeneca, Apo Biologix, Eli Lilly, Esai, Genomic Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics Inc, Pfizer, Roche, Seagen, Novartis, Purdue Pharma, Viatris and grants from AstraZeneca, Eli Lilly and Seagen outside the submitted work. All other authors declare no conflicts of interest.
: This is a population-based retrospective analysis. All personal identifiers for each case in this population cohort were removed. This study was facilitated through ICES which is named as a prescribed entity in Sect. 45 of PHIPA (Regulation 329/04, Sect. 18) which allows access and utilization of administrative data for research purposes with a waived requirement for consent.